Spondylometaphyseal dysplasia (SMD) is characterized by developmental changes in long bones and vertebrae. It has large phenotypic diversity and multiple genetic causes, including a recent link to novel variants in the extracellular matrix (ECM) protein fibronectin (FN), a regulator of ECM assembly and key link between the ECM and proper cell function. We identified a patient with a unique SMD, similar to SMD with corner fractures. The patient has been followed over 19 years and presents with short stature, genu varum, kyphoscoliosis, and pectus carinatum. 
| INTRODUCTION
The development of endochondral bone to form the vertebrate skeleton involves cell rearrangements and differentiation, remodeling of the extracellular matrix (ECM), localized growth factor signaling, and changes in gene expression. 1, 2 Tightly controlled changes in expression and assembly of the ECM components fibronectin (FN), collagens, and proteoglycans occur throughout chondrogenesis, in the growth plate, and at ossification sites. 3, 4 Defects in bone development cause skeletal dysplasias, which have been categorized into 42 groups based on phenotypic presentation and underlying pathophysiology. 5 Increasingly, genomic and exomic sequencing data have expanded our understanding of the types of genes and mutations that can cause skeletal dysplasias. 5 One type of dysplasia, the spondylometaphyseal dysplasia (SMD) group, is characterized radiographically as affecting the structure of the spine and metaphyses of long bones. 6 There are multiple types that differ in prevalence, etiology, and associated defects, such as corner fractures (MIM 184255) or cone-rod dystrophy (MIM 608940). 5 Mutations in genes encoding the ECM proteins collagen types II and X cause SMD, [7] [8] [9] but the genetic defects for many SMDs are unknown.
FN has recently been genetically linked to an SMD subtype, SMD with corner fractures (MIM 184255). 10 FN is a major component of most ECMs, forming a critical link between cells and structural components of the ECM. 11, 12 FN is secreted as a dimer and is assembled into polymeric fibrils by cell surface integrin receptors. Assembly depends on FN-FN interactions via the N-terminal assembly domain containing Eli B. Cadoff and Ruth Sheffer should be considered joint first author.
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the major FN binding site. 11 The resulting FN fibrillar network surrounds, connects to, and influences cells. Importantly, this FN network is essential for the incorporation of collagens, growth factors, and other ECM components into the matrix. [13] [14] [15] [16] The historical lack of FN mutations that lead to disease is thought to be a manifestation of FN's essential role in early development 17 ; homozygous null mutations in the FN gene are lethal. 17, 18 Therefore, the discovery of novel FN mutations linked to disease presents the opportunity to study the mechanisms through which a FN1 point mutation affects protein, cell, and developmental functions. Here, we present the case of a patient with SMD and identify a novel point mutation in the FN1 gene. We
show that primary cells from the affected patient secrete both wildtype (WT) and mutant FNs but assemble a reduced FN matrix.
| MATERIALS AND METHODS
The local institutional review board approved this study (HadassahHebrew University Hospital) in accordance with the World Medical Association Declaration of Helsinki. Informed consent was obtained from the parents of the affected patient and later the patient himself.
| Whole exome sequencing
For the affected patient and his parents, we performed whole exome sequencing using standard procedures. In brief, following DNA extraction from whole blood, sequencing was implemented on exon targets isolated by capture with the Agilent SureSelect Human All Exon V4
(50 Mb) Kit (Agilent Technologies, Santa Clara, CA, USA). DNA was sheared, ligated to adaptors, and purified for polymerase chain reaction (PCR) amplification, and products were captured according to the manufacturer's instructions. Sequences (100-bp paired-end) were generated on a HiSeq2500 (Illumina, San Diego, California, USA). Read alignment and variant calling were performed with DNAnexus (Palo Alto, California, USA) using default parameters with the human genome assembly hg19 (GRCh37) as reference. Probability calculations performed by 10 in silico prediction programs suggest that the identified FN1 mutation could have deleterious effects on protein function ( Figure S2A in Appendix S1). Figure S2D in Appendix S1).
| Mass spectrometry analysis of FN

| Isolation and culture of dermal fibroblasts
A skin biopsy was obtained from the affected patient, and FN C97W/+ dermal fibroblasts were isolated from the biopsy by standard procedures. For each condition, 10 images were taken across two biological replicates, minimum value was subtracted out as background signal, and
Student's t test was applied for statistical significance. Representative images were adjusted equivalently using FIJI. 28 such that it is the most prominent band detected by this analysis. Blots were developed using ECL (enhanced chemiluminescence substrate, Thermo Scientific), films were scanned, and bands within the linear range were quantified using FIJI. 29 Samples from at least three biological replicates were analyzed, and Student's t test was applied for statistical significance.
| Immunoblotting
3 | RESULTS
| Case report
The affected male is the fifth of seven children born to healthy, unrelated parents, with no family history of skeletal dysplasia. Mild intrauterine growth restriction was noted during pregnancy, which was otherwise normal. He was born by spontaneous vaginal delivery after 38 weeks of gestation, birth weight 2300 g, below third percentile.
There were no developmental problems in early infancy. Around the age of 1 year, short stature was noted. He started independent walking at the age of 1 year and 3 months. Subsequently, there was progressive asymmetric bowing of the legs and he developed a waddling gait. When he first presented to us at age 4, his height was 87.5 cm, below third percentile.
Radiographic studies began at age 2 years 10 months and MS was also used to determine the abundance of mutant FN relative to WT in vivo. Plasma FN was isolated from the blood of the patient. Plasma FN is produced and secreted by hepatocytes and thus is a source that is distinct from dermal cells. Peptides containing the single mutant amino acid change were detectable, but were significantly less abundant than WT peptides (~77% WT, 23% mutant; Figure S2D in Appendix S1). Figure S3A in Appendix S1) and grow at similar rates ( Figure S3B in Appendix S1). We compared these cells for the ability to assemble an FN matrix using indirect immunofluorescence staining. known cause of skeletal dysplasia. Increased retention of mutant ECM protein has been suggested as a pathogenic mechanism in other skeletal dysplasias. 9 The reduced production of FN could result in insufficient FN matrix assembly needed at the start of chondrogenesis for stem cell aggregation and differentiation. The fact that FN mutations linked to SMD are not embryonic lethal suggests that any affected processes are only delayed or otherwise altered, not entirely halted.
|
Indeed, variations in presentation and specific defects may be due to differences in the amount of mutant FN secreted, whether plasma FN can compensate, or whether cell viability is compromised by mutations. The localization of long bone changes to the metaphyses, the location of proliferative chondrocytes, suggests this cell type as a particular target in the phenotype described here. However, exactly how an FN matrix affects these chondrocytes remains a question worthy of further study. 
